Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future

Felix Mahfoud, Roland E. Schmieder, Michel Azizi, Atul Pathak, Horst Sievert, Costas Tsioufis, Thomas Zeller, Stefan Bertog, Peter J. Blankestijn, Michael Böhm, Michel Burnier, Gilles Chatellier, Isabelle Durand Zaleski, Sebastian Ewen, Guido Grassi, Michael Joner, Sverre E. Kjeldsen, Melvin D. Lobo, Chaim Lotan, Thomas Felix LüscherGianfranco Parati, Patrick Rossignol, Luis Ruilope, Faisal Sharif, Evert Van Leeuwen, Massimo Volpe, Stephan Windecker, Adam Witkowski, William Wijns

Research output: Contribution to journalReview article

Abstract

The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.

Original languageEnglish
Pages (from-to)3272-3281a
JournalEuropean Heart Journal
Volume38
Issue number44
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Hypertension
Equipment and Supplies
Technology
Therapeutics
Carotid Body
Baroreflex
Research
Patient Selection
Antihypertensive Agents
Uncertainty
Research Personnel
Outcome Assessment (Health Care)
Clinical Trials
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension : State of the art and considerations for the future. / Mahfoud, Felix; Schmieder, Roland E.; Azizi, Michel; Pathak, Atul; Sievert, Horst; Tsioufis, Costas; Zeller, Thomas; Bertog, Stefan; Blankestijn, Peter J.; Böhm, Michael; Burnier, Michel; Chatellier, Gilles; Zaleski, Isabelle Durand; Ewen, Sebastian; Grassi, Guido; Joner, Michael; Kjeldsen, Sverre E.; Lobo, Melvin D.; Lotan, Chaim; Lüscher, Thomas Felix; Parati, Gianfranco; Rossignol, Patrick; Ruilope, Luis; Sharif, Faisal; Van Leeuwen, Evert; Volpe, Massimo; Windecker, Stephan; Witkowski, Adam; Wijns, William.

In: European Heart Journal, Vol. 38, No. 44, 01.11.2017, p. 3272-3281a.

Research output: Contribution to journalReview article

Mahfoud, F, Schmieder, RE, Azizi, M, Pathak, A, Sievert, H, Tsioufis, C, Zeller, T, Bertog, S, Blankestijn, PJ, Böhm, M, Burnier, M, Chatellier, G, Zaleski, ID, Ewen, S, Grassi, G, Joner, M, Kjeldsen, SE, Lobo, MD, Lotan, C, Lüscher, TF, Parati, G, Rossignol, P, Ruilope, L, Sharif, F, Van Leeuwen, E, Volpe, M, Windecker, S, Witkowski, A & Wijns, W 2017, 'Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future', European Heart Journal, vol. 38, no. 44, pp. 3272-3281a. https://doi.org/10.1093/eurheartj/ehx215
Mahfoud, Felix ; Schmieder, Roland E. ; Azizi, Michel ; Pathak, Atul ; Sievert, Horst ; Tsioufis, Costas ; Zeller, Thomas ; Bertog, Stefan ; Blankestijn, Peter J. ; Böhm, Michael ; Burnier, Michel ; Chatellier, Gilles ; Zaleski, Isabelle Durand ; Ewen, Sebastian ; Grassi, Guido ; Joner, Michael ; Kjeldsen, Sverre E. ; Lobo, Melvin D. ; Lotan, Chaim ; Lüscher, Thomas Felix ; Parati, Gianfranco ; Rossignol, Patrick ; Ruilope, Luis ; Sharif, Faisal ; Van Leeuwen, Evert ; Volpe, Massimo ; Windecker, Stephan ; Witkowski, Adam ; Wijns, William. / Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension : State of the art and considerations for the future. In: European Heart Journal. 2017 ; Vol. 38, No. 44. pp. 3272-3281a.
@article{7316bc4379c5475f967deab1fc946bd0,
title = "Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future",
abstract = "The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.",
author = "Felix Mahfoud and Schmieder, {Roland E.} and Michel Azizi and Atul Pathak and Horst Sievert and Costas Tsioufis and Thomas Zeller and Stefan Bertog and Blankestijn, {Peter J.} and Michael B{\"o}hm and Michel Burnier and Gilles Chatellier and Zaleski, {Isabelle Durand} and Sebastian Ewen and Guido Grassi and Michael Joner and Kjeldsen, {Sverre E.} and Lobo, {Melvin D.} and Chaim Lotan and L{\"u}scher, {Thomas Felix} and Gianfranco Parati and Patrick Rossignol and Luis Ruilope and Faisal Sharif and {Van Leeuwen}, Evert and Massimo Volpe and Stephan Windecker and Adam Witkowski and William Wijns",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/eurheartj/ehx215",
language = "English",
volume = "38",
pages = "3272--3281a",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "44",

}

TY - JOUR

T1 - Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension

T2 - State of the art and considerations for the future

AU - Mahfoud, Felix

AU - Schmieder, Roland E.

AU - Azizi, Michel

AU - Pathak, Atul

AU - Sievert, Horst

AU - Tsioufis, Costas

AU - Zeller, Thomas

AU - Bertog, Stefan

AU - Blankestijn, Peter J.

AU - Böhm, Michael

AU - Burnier, Michel

AU - Chatellier, Gilles

AU - Zaleski, Isabelle Durand

AU - Ewen, Sebastian

AU - Grassi, Guido

AU - Joner, Michael

AU - Kjeldsen, Sverre E.

AU - Lobo, Melvin D.

AU - Lotan, Chaim

AU - Lüscher, Thomas Felix

AU - Parati, Gianfranco

AU - Rossignol, Patrick

AU - Ruilope, Luis

AU - Sharif, Faisal

AU - Van Leeuwen, Evert

AU - Volpe, Massimo

AU - Windecker, Stephan

AU - Witkowski, Adam

AU - Wijns, William

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.

AB - The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.

UR - http://www.scopus.com/inward/record.url?scp=85021253377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021253377&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehx215

DO - 10.1093/eurheartj/ehx215

M3 - Review article

AN - SCOPUS:85021253377

VL - 38

SP - 3272-3281a

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 44

ER -